PDE5A

PDE5A Full Name

phosphodiesterase 5A, cGMP-specific

PDE5A Introduction

PDE5A (phosphodiesterase 5A, cGMP-specific) is a dual-activity enzyme that hydrolyzes the secondary messenger cyclic guanosine monophosphate (cGMP) into its inactive linear form, 5'-GMP. It belongs to the large cyclic nucleotide phosphodiesterase (PDE) superfamily, with PDE5A being the sole member of its subfamily in humans. This enzyme exhibits high substrate specificity for cGMP over cAMP, a preference governed by a conserved glutamine residue in its catalytic pocket. Its expression is dynamically regulated in various tissues, and its activity is fine-tuned by post-translational modifications, making it a pivotal node in the nitric oxide (NO)-cGMP signaling cascade.The PDE5A protein is composed of three distinct structural regions: an N-terminal GAF-A domain, a GAF-B domain, and a C-terminal catalytic domain. The GAF domains (named after cGMP-binding proteins) are not merely structural; GAF-A serves as a non-catalytic cGMP-binding site that allosterically regulates enzymatic activity upon ligand occupancy. This binding induces a conformational change that exposes the catalytic site, enhancing substrate turnover. Additionally, the GAF-B domain contains a phosphorylation site (Ser92) targeted by protein kinase G (PKG) and protein kinase A (PKA), providing a feedback loop that either potentiates or inhibits enzyme function depending on cellular context and phosphorylation status.

Figure 1.PDE5A (phosphodiesterase 5a, cgmp-specific): CGMP degradation.

Clinical Significance and Pharmacological Targeting
PDE5A is the molecular target of the highly successful class of drugs known as PDE5 inhibitors, including sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra). These competitive inhibitors bind to the catalytic domain, preventing cGMP hydrolysis and thereby potentiating NO-mediated vasodilation. Their clinical applications have expanded beyond erectile dysfunction to include pulmonary arterial hypertension and benign prostatic hyperplasia. Interestingly, genetic variants in the PDE5A gene have been associated with differential drug responses, and recent research suggests that chronic inhibitor use may induce compensatory upregulation of the enzyme, posing challenges for long-term therapeutic efficacy in certain patient populations.

Emerging Research Frontiers Beyond Vasodilation
Beyond its canonical vascular roles, PDE5A is increasingly recognized as a driver in pathological fibrosis, cardiac hypertrophy, and even cancer progression. In fibroblasts, elevated PDE5A activity blunts the antifibrotic effects of cGMP, promoting collagen deposition in organs like the kidney and liver. In oncology, PDE5A overexpression has been linked to drug resistance in certain leukemias and solid tumors, where it modulates the tumor microenvironment via cGMP-dependent pathways. Currently, preclinical studies are exploring isoform-selective allosteric modulators that target the GAF domains rather than the catalytic pocket, aiming to achieve pathway-specific inhibition with fewer off-target side effects and greater tissue selectivity.

Alternate Names for PDE5A

PDE5A; phosphodiesterase 5A, cGMP-specific; CN5A; PDE5; CGB-PDE; cGMP-specific 3,5-cyclic phosphodiesterase; phosphodiesterase isozyme 5; cGMP-specific phosphodiesterase PDE5A2; cGMP-specific phosphodiesterase type 5A; cGMP-binding cGMP-specific 3,5-cyclic nucleotide phosphodiesterase;